Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Abstract

Background Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (FOLFIRI) is unknown. We aimed to compare these agents in patients with KRAS (exon 2) codon 12/13 wild-type metastatic colorectal cancer.Methods In this open-label, randomised, phase 3 trial, we recruited patients aged 18-75 years with stage IV, histologically confirmed colorectal cancer, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, an estimated life expectancy of greater than 3 months, and adequate organ function, from centres in Germany and Austria. Patients were centrally randomised by fax (1:1) to FOLFIRI plus cetuximab or FOLFIRI plus bevacizumab (using permuted blocks of randomly varying size), stratified according to ECOG performance status, number of metastatic sites, white blood cell count, and alkaline phosphatase concentration. The primary endpoint was objective response analysed by intention to treat. The study has completed recruitment, but follow-up of participants is ongoing. The trial is registered with ClinicalTrials.gov, number NCT00433927.Findings Between Jan 23, 2007, and Sept 19, 2012, 592 patients with KRAS exon 2 wild-type tumours were randomly assigned and received treatment (297 in the FOLFIRI plus cetuximab group and 295 in the FOLFIRI plus bevacizumab group). 184 (62·0%, 95% CI 56·2-67·5) patients in the cetuximab group achieved an objective response compared with 171 (58·0%, 52·1-63·7) in the bevacizumab group (odds ratio 1·18, 95% CI 0·85-1·64; p=0·18). Median progression-free survival was 10·0 months (95% CI 8·8-10·8) in the cetuximab group and 10·3 months (9·8-11·3) in the bevacizumab group (hazard ratio [HR] 1·06, 95% CI 0·88-1·26; p=0·55); however, median overall survival was 28·7 months (95% CI 24·0-36·6) in the cetuximab group compared with 25·0 months (22·7-27·6) in the bevacizumab group (HR 0·77, 95% CI 0·62-0·96; p=0·017). Safety profiles were consistent with the known side-effects of the study drugs. The most common grade 3 or worse adverse events in both treatment groups were haematotoxicity (73 [25%] of 297 patients in the cetuximab group vs 62 [21%] of 295 patients in the bevacizumab group), skin reactions (77 [26%] vs six [2%]), and diarrhoea (34 [11%] vs 40 [14%]).Interpretation Although the proportion of patients who achieved an objective response did not significantly differ between the FOLFIRI plus cetuximab and FOLFIRI plus bevacizumab groups, the association with longer overall survival suggests that FOLFIRI plus cetuximab could be the preferred first-line regimen for patients with KRAS exon 2 wild-type metastatic colorectal cancer.Funding Merck KGaA.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(14)70330-4

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 27 references

Research works printed but not linked: 1

  1. Venook, 2014, Proc Am Soc Clin Oncol, 32, LBA3, 10.1200/jco.2014.32.18_suppl.lba3 · doi:10.1200/jco.2014.32.18_suppl.lba3 · Paper page

Cited by

See all 1,740

Metadata

Authors
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., Kullmann, F., Stauch, M., Scheithauer, W., Hielscher, J., Scholz, M., Müller, S., Link, H., Niederle, N., Rost, A., Höffkes, H.-G., Moehler, M., Lindig, R. U., Modest, D. P., Rossius, L., Kirchner, T., Jung, A., & Stintzing, S.
Affiliations
  • Ludwig-Maximilians-Universität München (DE)
  • Bayreuth Medical Center (DE)
  • Klinikum Magdeburg (DE)
  • Klinikum Weiden (DE)
  • Comprehensive Cancer Center Vienna (AT)
  • Klinikum Chemnitz (DE)
  • Klinikum Stuttgart (DE)
  • Westpfalz Klinikum (DE)
  • Klinikum Leverkusen (DE)
  • Klinikum Darmstadt (DE)
  • Klinikum Fulda (DE)
  • Johannes Gutenberg University Mainz (DE)
  • Jena University Hospital (DE)
  • Pathologisches Institut (DE)
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2014-09
Volume
15
Issue
10
Pages
1065-1075
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2005348280
Cited by
1,740
References
27
Citations by year
2026: 57 · 2025: 82 · 2024: 105 · 2023: 114 · 2022: 136 · 2021: 147 · 2020: 153 · 2019: 162 · 2018: 171 · 2017: 175 · 2016: 201 · 2015: 205 · 2014: 30
FWCI
98.39
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Merck KGaA
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords
metastatic colorectal cancer, FOLFIRI, cetuximab, bevacizumab, first-line chemotherapy, KRAS exon 2 wild-type, anti-EGFR therapy, anti-VEGF therapy, objective response, progression-free survival, overall survival, treatment toxicity, irinotecan, 5-fluorouracil, leucovorin, FIRE-3 trial
MeSH terms
Bevacizumab, Cetuximab, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Austria, Camptothecin, Leucovorin, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Fluorouracil, Germany, Humans, Infusions, Intravenous, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Prognosis, Colorectal Neoplasms, Survival Rate, Treatment Outcome, Disease-Free Survival, Patient Selection, Maximum Tolerated Dose, Young Adult, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(14)70330-4
The paper
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., Kullmann, F., Stauch, M., Scheithauer, W., Hielscher, J., Scholz, M., Müller, S., Link, H., Niederle, N., Rost, A., . . . Stintzing, S. (2014). FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(14)70330-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.